Editas Medicine (EDIT) Reports In-Line Q1 EPS

Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.79), in-line with the analyst estimate of ($0.79). Revenue for the quarter came in at $9.9 million versus the consensus estimate of $3.29 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance
• Oddity Tech Ltd. (ODD) Tops Q2 EPS by 1c
• ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance